MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geovax Labs (NQ: GOVX )

2.242 +0.292 (+14.97%)
Streaming Delayed Price Updated: 12:37 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geovax Labs

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst
Geovax Labs stock is up on Tuesday as GOVX investors are excited about a potential catalyst for the company's shares on July 18. 
Via InvestorPlace
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Company to Discuss Recent BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine and Provide Progress Update Across Its Clinical Development Pipeline 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax Provides First Half 2024 Business Update
Via NewMediaWire
(GOVX) - Analyzing Geovax Labs's Short Interest
Via Benzinga
Why Is GeoVax (GOVX) Stock Up 110% Today?
With Covid-19 still representing a major problem, GeoVax’s next-gen Covid vaccine may help, bolstering GOVX stock. 
Via InvestorPlace
Exposures COVID-19
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
Why GeoVax Labs Stock Is Moving Higher Thursday
GeoVax Labs received a BARDA Project NextGen award to conduct a study evaluating its COVID-19 vaccine candidate GEO-CM04S1. 
Via Benzinga
Exposures COVID-19
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
GeoVax to Present at BIO International Convention 2024
Via TheNewswire.com
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning! 
Via InvestorPlace
GeoVax to Present at BIO International Convention 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - May 17, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
GOVX Stock Earnings: Geovax Labs Beats EPS for Q1 2024
GOVX stock results show that Geovax Labs beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate 
Via TheNewswire.com
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story